Lesson
Use Stress-Ulcer Prophylaxis Only While Risk Persists
Stress-related mucosal bleeding prevention is a temporary risk intervention. Coagulopathy, shock, and chronic liver disease are the clearest current risk factors, while enteral nutrition, ventilation, neurologic illness, and preexisting acid disease also inform the decision.
- Risk stratification
- PPI
- H2RA
- Enteral nutrition
- Deprescribing
Coagulopathy, shock, and chronic liver disease carry the clearest current signal.
Use a low-dose enteral or intravenous option when risk justifies exposure.
Discontinue when risk resolves and avoid an unnecessary discharge medicine.
Separate ICU location from bleeding risk
The 2024 SCCM and ASHP guideline identifies coagulopathy, shock, and chronic liver disease as likely risk factors for clinically important stress-related upper gastrointestinal bleeding. Its evidence review did not establish ventilation alone as an independent risk factor. The 2026 Saudi/Nordic contextualized guideline incorporates newer evidence and advises individualized assessment of ventilated patients as potentially at risk. Do not interpret the earlier uncertainty as proof that ventilated patients cannot benefit.
Choose a low-dose preventive regimen
The 2024 SCCM/ASHP guideline accepts either a proton pump inhibitor or histamine-2 receptor antagonist for adults who remain at risk. Enteral and intravenous routes are both acceptable when clinically feasible. Drug interactions, kidney function, enteral access, prior acid disease, and local protocol should determine the exact regimen.
Apply sepsis-specific guidance
For adults with sepsis or septic shock and gastrointestinal bleeding risk factors, the 2026 Surviving Sepsis Campaign conditionally suggests PPI prophylaxis rather than no prophylaxis, with moderate-certainty evidence. This comparison does not establish PPI superiority over H2 blockers or make prophylaxis automatic for every patient with sepsis. Keep risk assessment, dose selection and stopping rules explicit.
Define low dose and distinguish active bleeding
SCCM/ASHP defines low-dose daily totals as at most 40 mg for pantoprazole, omeprazole or esomeprazole; 30 mg for lansoprazole; and 40 mg for famotidine. These are preventive dose categories, not a universal prescription: renal function and product-specific administration still matter. Active gastrointestinal bleeding requires its own evaluation and treatment pathway.
Account for feeding and neurologic illness
Enteral feeding does not cancel persistent bleeding risk. SCCM/ASHP suggests prophylaxis for at-risk adults even when fed, and separately suggests it in neurocritical-care adults, with very low certainty for both recommendations. A low-risk, fed patient is a different case from a fed patient with coagulopathy.
Preserve an independent treatment indication
A PPI used before ICU admission may be treating recent bleeding, erosive esophagitis, a hypersecretory condition or active H. pylori infection. Reconcile that indication before stopping it. If the history is unclear, clarify it instead of assuming the drug was started solely for ICU prophylaxis.
Stop when the reason ends
Enteral nutrition probably reduces bleeding risk, and low-risk patients receiving enteral nutrition should not receive routine prophylaxis. Review the indication daily, discontinue when the risk factor resolves, and avoid carrying prophylaxis through ICU transfer or discharge unless a separate indication remains.
Quick check
Checking for saved practice…
Lesson
Map Local Anesthetic Effect and Disposition
Local anesthetics must cross tissue and membrane, enter the axon, and bind voltage-gated sodium channels from the intracellular side. Molecular state, tissue pH, lipid solubility, protein binding, blood flow, dose, and metabolism shape onset, potency, duration, and toxicity.
- Sodium channels
- Ionization
- Amides
- Esters
- Additive toxicity
Uncharged drug moves through tissue and axonal membrane.
Protonated drug reaches the intracellular sodium-channel site.
Dose, blood flow, organ function, and every local anesthetic shape systemic risk.
Connect pH to access and block
The uncharged fraction crosses lipid membrane, while the protonated form binds within the sodium channel. Inflamed acidic tissue shifts drug toward ionization before membrane entry and can slow or weaken block. Use-dependent binding favors channels that open repeatedly, which explains selective suppression of rapidly firing fibers.
Distinguish disposition families
Amide agents such as lidocaine, bupivacaine, and ropivacaine are metabolized mainly in the liver. Ester agents are hydrolyzed largely by plasma cholinesterases and can generate para-aminobenzoic-acid-related metabolites. Patient physiology, not the suffix alone, determines the complete safety plan.
Match the formulation to the route
Bupivacaine is not interchangeable across every regional technique. Standard injection labeling contraindicates intravenous regional anesthesia (Bier block) and obstetrical paracervical block. The 0.75% concentration is not recommended for obstetrical anesthesia. Preservative-containing multidose vials should not be used for epidural or caudal anesthesia; verify the exact product rather than assuming every bupivacaine vial is suitable for spinal use.
Adjust exposure and distrust a negative aspiration
Consider lower doses and closer toxicity monitoring with moderate or severe hepatic impairment, particularly with repeated bupivacaine dosing. Reduced doses are also needed with impaired cardiovascular function. Aspirate and inject incrementally as appropriate, but a negative aspiration cannot exclude intravascular or intrathecal placement. Continue monitoring after each injection.
Treat all exposure as one toxicity budget
Local-anesthetic systemic toxicity is additive across products. Use the lowest effective dose, aspirate where appropriate, administer fractionally when feasible, monitor consciousness, ventilation, rhythm, and circulation, and maintain immediate access to oxygen, resuscitation equipment, skilled personnel, and a LAST kit.
Quick check
Checking for saved practice…
Lesson
Treat Local Anesthetic Systemic Toxicity as a Distinct Arrest Pathway
LAST can begin with perioral symptoms, tinnitus, altered speech, agitation, or seizure, but severe cardiovascular toxicity can appear abruptly. The rescue sequence differs from standard ACLS because several familiar resuscitation drugs can worsen local-anesthetic cardiotoxicity.
- Recognition
- Airway
- Lipid emulsion
- Modified ACLS
- Observation
Prevent hypoxemia, hypercapnia, and acidosis while controlling seizure.
Use the current ASRA weight-based bolus and infusion pathway.
Use smaller epinephrine and avoid vasopressin and other aggravating drugs.
Stop exposure and stabilize physiology
Stop injection, call for help, secure oxygenation and ventilation, and prevent acidosis, hypoxemia, and hypercapnia that can intensify toxicity. Prefer a benzodiazepine for seizure when available. Do not wait for a complete textbook progression before activating the rescue pathway.
Give 20 percent lipid emulsion early
For patients under 70 kg, the ASRA checklist uses an approximately 1.5 mL/kg bolus over 2 to 3 minutes followed by about 0.25 mL/kg/min. For patients over 70 kg, it provides approximately 100 mL over 2 to 3 minutes followed by about 250 mL over 15 to 20 minutes. Persistent instability calls for a repeat bolus and doubled infusion while respecting the checklist maximum of 12 mL/kg.
Keep the bolus, rate and total separate
For a 60-kg patient, 1.5 mL/kg gives a 90-mL bolus. The initial 0.25 mL/kg/min infusion is 15 mL/min, or 900 mL/hour. The 12 mL/kg cumulative ceiling is 720 mL, counting boluses and infusion together; it is not an initial bolus. Reassess circulation continuously and obtain expert support for persistent instability.
Modify the resuscitation medicines
When epinephrine is needed, start with smaller doses below 1 microgram/kg. Avoid vasopressin, beta blockers, calcium-channel blockers, additional local anesthetic, and other listed aggravating agents. Continue observation after stability because recurrence can occur, and obtain expert or bypass support when the course is refractory.
Keep propofol separate from rescue lipid
Propofol is not a substitute for 20% lipid rescue. Delivering the necessary lipid quantity through propofol would expose the patient to a dangerous anesthetic dose.
Continue treatment and observation
The ASRA checklist continues lipid for more than 15 minutes after hemodynamic stability, within the cumulative maximum. Observe for 2 hours after seizure or 4 to 6 hours after cardiovascular instability; individualize post-arrest monitoring and reassess any recurrence.
Quick check
Checking for saved practice…
Lesson
Choose Induction Through Physiology
Propofol, etomidate, and ketamine can all produce hypnosis, but their cardiovascular, respiratory, endocrine, analgesic, and recovery effects are different. The correct choice begins with the patient's current physiologic constraint and the airway plan.
- Propofol
- Etomidate
- Ketamine
- Hemodynamics
- Airway
Fast hypnosis and recovery can cost pressure and ventilation.
Relative hemodynamic stability trades against myoclonus and adrenal suppression.
Often stimulating, but not immune to apnea, emergence, or catecholamine-depleted collapse.
Use propofol when rapid control fits the reserve
Propofol provides rapid hypnosis and titratable recovery but can cause apnea, vasodilation, myocardial depression, and severe hypotension. Reduce and titrate exposure in older, debilitated, hypovolemic, or unstable patients and ensure immediate ventilatory and circulatory support.
Treat propofol as a contamination-sensitive emulsion
Use strict aseptic technique and a single-patient preparation. For the cited product, discard unused drug and dedicated tubing at procedure completion or 12 hours, whichever comes first; ICU drug and tubing also require replacement by 12 hours. Ingredients that slow microbial growth do not permit reuse between patients. Check the actual formulation because excipients differ.
Recognize infusion toxicity and count lipid calories
New metabolic acidosis, rhabdomyolysis, hyperkalemia or cardiac failure during a propofol infusion raises concern for propofol infusion syndrome. Stop propofol promptly and manage the deterioration with an alternative sedation plan. High doses and prolonged exposure increase risk, but shorter exposure does not exclude it. Monitor lipid tolerance and account for approximately 1.1 kcal per mL in nutrition planning.
Distinguish food allergy from a propofol reaction
AAAAI guidance states that egg or soy allergy alone does not require special precautions with propofol; food-protein allergy does not establish allergy to its lipid vehicle. The cited product label nevertheless lists egg, soybean and propofol hypersensitivity as contraindications. Document this difference and have the anesthesia team reconcile the specific history, product and local policy. A previous suspected propofol reaction is a separate concern requiring allergy evaluation; do not dismiss it as a food-allergy myth.
Keep pediatric indications distinct
The cited propofol label supports induction from age 3 years and maintenance from age 2 months. These anesthesia indications do not establish pediatric ICU sedation approval. Pediatric ICU use is not a labeled indication and requires a separate evidence-based specialist decision.
Use etomidate with endocrine honesty
Etomidate often preserves pressure better during induction but commonly causes injection pain and myoclonus. A single induction dose can reduce cortisol and aldosterone concentrations through adrenal steroid-synthesis inhibition. The clinical tradeoff is limited immediate cardiovascular depression versus a measurable endocrine effect.
Separate etomidate induction from ongoing care
Etomidate produces hypnosis without analgesia. Plan pain treatment separately and establish ongoing sedation when paralysis or mechanical ventilation continues. Its labeling warns against prolonged infusion because adrenal suppression can persist. Apnea and airway obstruction remain possible; relative cardiovascular stability does not remove the need for rescue equipment or monitoring.
Calculate an individualized induction dose
The labeled usual etomidate induction dose is 0.3 mg/kg IV over 30 to 60 seconds, individualized within the labeled range. For a prescribed 0.3 mg/kg dose in a 70 kg adult, 21 mg requires 10.5 mL of the 2 mg/mL solution. Older patients may need less. This calculation checks a specified order; it does not establish the best dose for every patient.
Use ketamine without calling it fail-safe
Ketamine adds analgesia and often increases pressure and pulse. Emergence reactions, hypersalivation, airway obstruction, laryngospasm, and respiratory depression after rapid high dosing remain possible. Catecholamine-depleted patients can develop falling pressure or cardiac decompensation, and coadministration with other CNS depressants increases respiratory risk.
Check ketamine concentration before injection
For this labeled product, 100 mg/mL ketamine requires equal-volume dilution with sterile water, normal saline or D5W before IV induction; use immediately. The resulting concentration is 50 mg/mL. A prescribed 100 mg dose therefore occupies 2 mL after dilution. Slow IV administration matters because rapid dosing increases respiratory and pressor effects.
Screen the procedure and interacting drugs
Ketamine is contraindicated when a substantial blood-pressure rise would be dangerous. Retained airway reflexes do not prevent aspiration or make ketamine suitable as the sole anesthetic for pharyngeal, laryngeal or bronchial procedures. Theophylline and aminophylline can lower the seizure threshold with ketamine; consider another anesthetic. Reduce stimulation during emergence while continuing monitoring.
Reassess recurrent ketamine exposure
Recurrent treatment requires baseline and periodic liver tests. The 2026 label adds detail on biliary injury and urinary obstruction: suspected sclerosing cholangitis warrants immediate discontinuation and specialist assessment; severe urinary symptoms or obstruction warrant discontinuation and urgent urological evaluation. These longer-exposure risks differ from immediate induction complications.
Quick check
Checking for saved practice…
Lesson
Recognize and Interrupt Malignant Hyperthermia
Malignant hyperthermia is uncontrolled skeletal-muscle calcium release in susceptible patients after volatile anesthetics, succinylcholine, or both. Rising carbon dioxide and rigidity can precede dramatic temperature elevation, so treatment begins from the pattern rather than a late threshold.
- Triggers
- Hypercapnia
- Dantrolene
- Cooling
- Recurrence
Early hypercapnia, tachycardia, acidosis, and muscle rigidity define the pattern.
Stop volatile agents and succinylcholine, then give repeated actual-weight dantrolene.
Cool, correct potassium and acidosis, protect kidneys, and monitor recurrence.
Recognize the hypermetabolic pattern
Unexpected rapid carbon-dioxide rise despite ventilation, tachycardia, masseter or generalized rigidity, mixed acidosis, hyperkalemia, rhabdomyolysis, and increasing temperature should activate the crisis response. Stop volatile agents and succinylcholine immediately and call for help and the malignant-hyperthermia cart.
Give dantrolene and oxygen without delay
Hyperventilate with 100 percent oxygen at high flow, remove or disable volatile delivery, use activated charcoal filters when available, and give dantrolene 2.5 mg/kg intravenously using actual body weight. Repeat rapidly until carbon dioxide, rigidity, rate, temperature, and metabolic instability improve. Under MHAUS guidance, total dosing can exceed 10 mg/kg; persistent nonresponse also requires reassessment for alternative diagnoses.
Distinguish protocol dosing from product labeling
The MHAUS crisis pathway starts at 2.5 mg/kg. RYANODEX labeling starts at a minimum of 1 mg/kg and lists a 10 mg/kg cumulative maximum. Escalation beyond that label limit belongs to expert-directed MHAUS crisis management, not an unqualified labeled-dose claim.
Prepare the product actually stocked
MHAUS lists 20-mg DANTRIUM or REVONTO vials mixed with 60 mL preservative-free sterile water for injection; RYANODEX uses 250 mg with 5 mL of that diluent. Do not interchange their preparation volumes. RYANODEX forms an opaque orange suspension, must be used within 6 hours, and must not be further diluted or transferred to an infusion container. Verify IV patency and watch for extravasation.
Separate calcium treatment from calcium-channel blockers
Avoid calcium-channel blockers during dantrolene treatment of MH because severe hyperkalemia and cardiovascular collapse have been reported. This does not prohibit IV calcium salts when indicated for life-threatening hyperkalemia. Continue ECG, potassium and glucose monitoring while treating the crisis.
Plan maintenance and a clinical stopping rule
MHAUS advises dantrolene 1 mg/kg IV every 4 to 6 hours for at least 24 hours, longer if needed. Consider stopping or spacing doses only after 24 hours of metabolic stability, temperature below 38 C, falling CK, resolved rigidity and no ongoing myoglobinuria. Monitor ventilation, swallowing, muscle strength and the IV site; apparent initial recovery is not the end of care.
Correct complications and prevent recurrence
MHAUS starts cooling above 39 C, or earlier if temperature is rising rapidly, and stops cooling below 38 C. Concurrently treat hyperkalemia and dysrhythmia, and monitor gases, potassium, glucose, CK, urine, coagulation, kidney function, and core temperature. Continue MHAUS-directed dantrolene and intensive observation because recrudescence can occur after apparent control.
Quick check
Checking for saved practice…
Lesson
Understand Block Before Choosing a Drug
Neuromuscular blockers prevent skeletal-muscle contraction at nicotinic acetylcholine receptors. Succinylcholine depolarizes the end plate, while nondepolarizing agents competitively block receptor activation. Neither mechanism supplies pain relief, amnesia, or unconsciousness.
- Motor end plate
- Depolarizing block
- Competitive block
- No sedation
- Recovery
Persistent end-plate activation produces phase I paralysis.
Receptor antagonism prevents acetylcholine from generating contraction.
Sedation, analgesia, ventilation, and monitoring remain separate requirements.
Read the neuromuscular junction
Motor neurons release acetylcholine, which binds postsynaptic nicotinic receptors and opens cation channels. A sufficient end-plate potential activates nearby voltage-gated sodium channels and produces muscle contraction. Acetylcholinesterase rapidly terminates the signal.
Separate depolarizing from competitive block
Succinylcholine initially activates the receptor and produces fasciculation, then persistent depolarization prevents repeated contraction during phase I block. Rocuronium, vecuronium, cisatracurium, and related agents compete with acetylcholine without activating the receptor.
Keep consciousness visible when movement disappears
Paralysis removes movement and respiratory-muscle function but leaves the brain capable of pain, memory, fear, and awareness. Adequate sedation and analgesia must be established before paralysis and maintained independently throughout its effect.
Quick check
Checking for saved practice…
Lesson
Use Succinylcholine Only After a Risk Screen
Succinylcholine has rapid onset and a short usual duration, but its depolarizing mechanism creates distinctive hyperkalemia, bradycardia, malignant-hyperthermia, myalgia, pressure, pediatric, and prolonged-apnea hazards.
- Hyperkalemia
- Pediatric warning
- Bradycardia
- Malignant hyperthermia
- Pseudocholinesterase
Denervation, burns, immobility, myopathy, and injury can amplify potassium release.
The boxed warning limits routine pediatric convenience use.
Ventilate and maintain unconsciousness until objective recovery is complete.
Identify receptor-upregulation risk
After major burns, denervation, spinal-cord or peripheral-nerve injury, prolonged immobilization, stroke-related paralysis, or neuromuscular disease, extrajunctional receptors can produce dangerous potassium release. The risk evolves over time and cannot be reduced to one universal day count.
Respect the pediatric boxed warning
Hyperkalemic rhabdomyolysis, ventricular dysrhythmia, arrest, and death have occurred in children with unrecognized skeletal-muscle myopathy. Reserve pediatric succinylcholine for emergency airway control or situations where the airway must be secured immediately.
Anticipate bradycardia and pressure effects
Succinylcholine can cause profound bradycardia or rarely asystole, especially in children and after repeat doses in adults or children. Anticholinergic pretreatment such as atropine may reduce this risk; it does not prevent hyperkalemic arrest. Monitor rhythm and reassess the cause of deterioration. The label also cautions about increased intraocular pressure: with penetrating eye injury or narrow-angle glaucoma, use requires a benefit-risk judgment rather than an assumption of harmless short exposure.
Support prolonged block rather than guessing
Plasma-cholinesterase deficiency, pregnancy, liver disease, malnutrition, organophosphates, and selected medicines can prolong block. Continue controlled ventilation and adequate unconsciousness until quantitative recovery. Phase I block is not treated like shallow nondepolarizing block, and reflexive neostigmine can prolong it.
Confirm phase II before considering reversal
Prolonged succinylcholine exposure can produce phase II block. The label requires nerve-stimulator confirmation plus at least 20 minutes of spontaneous twitch recovery that has reached a slowly recovering plateau before considering anticholinesterase reversal. This is an anesthesia-specialist decision; phase I misclassification can prolong paralysis. If reversal is selected, provide antimuscarinic protection and observe for recurrent weakness for at least one hour. Continue ventilation and adequate anesthesia as needed.
Quick check
Checking for saved practice…
Lesson
Select Nondepolarizing Block With Recovery in Mind
The useful onset of rocuronium, the aminosteroid disposition of rocuronium and vecuronium, and the organ-independent Hofmann elimination of cisatracurium create different tradeoffs. Volatile anesthetics, magnesium, antibiotics, temperature, acid-base state, and cumulative dose can all change duration.
- Rocuronium
- Vecuronium
- Cisatracurium
- Hofmann elimination
- Interactions
Rapid intubation is followed by variable hepatobiliary and renal recovery.
Organ dysfunction and active metabolite can extend block.
Organ-independent degradation is useful, but pH, temperature, and monitoring still matter.
Use rocuronium for rapid onset with a complete exit plan
Rocuronium is labeled for rapid-sequence and routine intubation plus skeletal-muscle relaxation during surgery or mechanical ventilation. Its duration varies substantially and can be prolonged by organ dysfunction, volatile anesthetics, magnesium, aminoglycosides, and cumulative dosing.
Check the population before applying the indication
The cited U.S. rocuronium label does not recommend rapid-sequence intubation in pediatric patients or rapid-sequence induction for cesarean delivery. These population-specific limitations should accompany the general intubation indication. They are distinct from the label’s contraindication for known hypersensitivity to rocuronium or other neuromuscular blockers. Pediatric routine intubation and surgical maintenance are separate uses; do not infer pediatric rapid-sequence approval from them.
Reconcile obstetric guidance with labeling
The OAA/DAS obstetric airway guideline describes rocuronium 1.0 to 1.2 mg/kg with immediately available, preplanned sugammadex as an alternative to succinylcholine. This specialist guidance differs from the cited U.S. product label. Use an obstetric anesthesia protocol that addresses this difference, patient risks, ventilation, and failed-intubation rescue. Reversal availability does not remove the need to maintain oxygenation or prevent aspiration and awareness when intubation fails.
Recognize aminosteroid disposition
Rocuronium is eliminated mainly through hepatobiliary pathways with some renal contribution. Vecuronium and its active 3-desacetyl metabolite have biliary and renal elimination. Prolonged exposure, especially in the ICU, can create a different recovery problem from a single surgical dose. Kidney and liver function, cumulative exposure and measured recovery must inform the plan.
Use cisatracurium when organ-independent elimination fits
Cisatracurium undergoes Hofmann degradation, reducing dependence on kidney and liver. Temperature and pH still influence degradation, and prolonged use still requires objective monitoring, full sedation, ventilation, and daily indication review.
Separate parent-drug clearance from metabolite exposure
Cisatracurium metabolites still require renal and hepatic clearance and can accumulate during prolonged treatment when those organs are impaired. Laudanosine does not cause neuromuscular block, but it has produced seizures in animals; the human concentration-to-CNS-effect relationship is not established. Monitor the degree of blockade and limit unnecessary exposure. Vecuronium differs: its 3-desacetyl metabolite retains neuromuscular-blocking activity and may contribute to prolonged paralysis.
Quick check
Checking for saved practice…
Lesson
Make Paralysis a High-Reliability System
A wrong-vial event can cause silent respiratory arrest, and intended paralysis can hide awareness, pain, seizures, pressure injury, and ventilatory failure. Safe use depends on storage engineering and a bedside care bundle, not on memory alone.
- Segregation
- Paralyzing-agent warning
- Ventilation
- Sedation
- Supportive care
Restrict access and use unmistakable paralyzing-agent warnings.
Confirm mechanical support, analgesia, sedation, and indication before dosing.
Maintain eye, skin, thrombosis, positioning, temperature, and daily stop safeguards.
Prevent accidental selection
ISMP recommends removing neuromuscular blockers from areas where they are not routinely used. Where needed, secure them in sealed kits or lock-lidded dispensing-cabinet bins. In the pharmacy, separate them from other medicines in lidded refrigerator containers or secure isolated storage. A warning sticker alone does not make unnecessary ward stock appropriate.
Make removal and labeling deliberate
Configure dispensing cabinets to require a clinical response, such as the indication or ventilation status, before releasing the drug. Final containers and storage locations need conspicuous respiratory-paralysis and ventilation warnings without hiding essential medication information. ISMP exempts anesthesia-prepared syringes from its auxiliary-warning practice; this is not permission to omit the drug identity.
Verify before and after administration
Use pharmacist-verified profiles when possible, barcode scanning, independent checks for indication and ventilation, labeled syringes, and immediate documentation. Use explicit neuromuscular-blocker and paralyzing-agent terminology in storage and safety communication; a muscle-relaxant label alone can obscure respiratory-arrest risk.
Decide whether ICU blockade is needed
The 2026 SCCM ARDS guideline conditionally favors neuromuscular blockade when PaO2/FiO2 is below 150 and hypoxemia persists or ventilation targets remain unmet despite sedation. Certainty is low. Prone positioning alone does not require paralysis; assess the actual oxygenation and ventilation problem.
Choose the regimen for the clinical setting
For adults with sepsis and moderate-to-severe ARDS, the 2026 Surviving Sepsis Campaign conditionally favors intermittent boluses over continuous infusion, with moderate-certainty evidence. A care bundle for an infusion does not establish that every ventilated patient needs one. Reassess indication and exposure as physiology changes.
Separate ICU dosing from surgical recovery
The SCCM ARDS guideline allows either fixed dosing without block-depth monitoring or titration guided by block depth, with very low certainty. This differs from ASA quantitative monitoring for surgical recovery and extubation. Uncertainty about the best ICU monitoring strategy does not remove the requirement for adequate analgesia, sedation and ventilation; paralysis itself supplies none of them.
Protect the immobilized patient
Maintain mechanical ventilation, adequate analgesia and sedation, eye lubrication and closure, pressure and skin care, thrombosis prevention, positioning, temperature control, and repeated neuromuscular assessment. Review ongoing need and use the lowest effective exposure.
Quick check
Checking for saved practice…
Lesson
Measure Recovery and Match the Reversal
Clinical signs and subjective twitch counts miss residual paralysis. Quantitative adductor-pollicis monitoring establishes block depth, selects the reversal approach, and confirms a train-of-four ratio of at least 0.9 before extubation.
- Quantitative TOF
- Sugammadex
- Neostigmine
- Antimuscarinic
- Extubation
Use adductor-pollicis monitoring rather than strength tests or elapsed time.
Match sugammadex or neostigmine to the blocker and objective depth.
Do not extubate until quantitative recovery and airway readiness are established.
Use objective recovery
The ASA recommends quantitative rather than clinical or qualitative assessment when neuromuscular blockers are used. Monitor at the adductor pollicis and confirm a train-of-four ratio at or above 0.9 before extubation. Head lift, grip, and tidal volume do not reliably exclude residual weakness.
Dose sugammadex from measured depth
Sugammadex reverses rocuronium and vecuronium. Current labeling uses actual body weight: 2 mg/kg at reappearance of T2, 4 mg/kg with 1 to 2 post-tetanic counts and no train-of-four twitch, and 16 mg/kg for the labeled immediate-reversal scenario about 3 minutes after 1.2 mg/kg rocuronium. It is not recommended in severe renal impairment and does not reverse succinylcholine or cisatracurium.
Do not extend sugammadex to every steroidal blocker
Pancuronium is not an additional BRIDION target. The label directs against reversal of steroidal blockers other than rocuronium or vecuronium, as well as nonsteroidal blockers. Identify the administered agent before selecting reversal; a shared drug class does not establish interchangeability. Maintain ventilation and sedation while an appropriate recovery plan is made.
Distinguish pediatric reversal from immediate rescue
BRIDION labeling now includes surgical reversal of rocuronium or vecuronium in pediatric patients from birth. Use the measured-depth regimens rather than an age-based fixed dose. Immediate reversal in children has not been studied; do not present the adult 16 mg/kg rocuronium scenario as established pediatric rescue. The book’s adult-only description does not capture this expanded indication.
Measure small doses accurately
For pediatric measurement, BRIDION 100 mg/mL may be diluted with 0.9% sodium chloride to 10 mg/mL: add the 200 mg in a 2 mL vial to 18 mL diluent and use immediately. A 5 kg infant at reappearance of T2 requires 10 mg, or 1 mL of this diluted solution. Independently verify concentration and continue ventilation until airway and breathing recovery are adequate.
Monitor the patient after reversal
Continue ventilatory support until breathing and airway protection are adequate, even after TOF recovery. Sugammadex can cause anaphylaxis or marked bradycardia, including cardiac arrest. Monitor closely and treat clinically significant bradycardia with an anticholinergic such as atropine. Underdosing or interacting drugs can permit recurrent weakness; toremifene can delay recovery.
Respect the studied setting and bleeding context
BRIDION is labeled for surgical reversal; the label states that reversal after ICU rocuronium or vecuronium use has not been studied. Do not assume that prolonged ICU blockade has the same evidence as surgical dosing. Transient increases in PT/INR and aPTT can occur. Carefully monitor coagulation in known coagulopathy, therapeutic anticoagulation, or other higher-risk situations described in the label. A trial using 4 mg/kg with heparin or low-molecular-weight heparin prophylaxis did not show increased bleeding, but this does not establish safety for every anticoagulant or dose.
Include contraception in discharge counseling
After sugammadex, patients using hormonal contraception need an additional nonhormonal method for seven days. This applies to oral and nonoral methods. Document counseling before discharge; the interaction is not limited to contraceptive pills.
Plan any repeat blockade from the reversal dose
After up to 4 mg/kg sugammadex, the label specifies at least five minutes before rocuronium 1.2 mg/kg, or four hours before rocuronium 0.6 mg/kg or vecuronium 0.1 mg/kg. Early rocuronium can act later and wear off sooner. Mild or moderate renal impairment extends the latter two regimens to 24 hours; an earlier plan requires the higher rocuronium regimen. After 16 mg/kg sugammadex, a 24-hour interval is suggested. If blockade is needed before the applicable interval, use a suitable nonsteroidal agent with its own contraindications and monitoring.
Use neostigmine after spontaneous recovery
ASA considers neostigmine an alternative at minimal blockade, defined by a quantitative TOF ratio of 0.4 to less than 0.9; sugammadex is preferred for deeper rocuronium or vecuronium block. At minimal block, ASA advises no more than 40 micrograms/kg (0.04 mg/kg). A ratio already at least 0.9 does not require pharmacologic antagonism; airway readiness still needs assessment.
Screen before neostigmine reversal
BLOXIVERZ is contraindicated with neostigmine hypersensitivity, peritonitis, or mechanical intestinal or urinary obstruction. Coronary disease, arrhythmias, recent acute coronary syndrome and myasthenia gravis require caution. Excessive dosing near recovery can itself cause neuromuscular dysfunction; more reversal drug does not necessarily produce stronger muscles. Maintain ventilation and objective monitoring while the team selects a suitable recovery plan.
Separate the label ceiling from depth-based dosing
BLOXIVERZ labeling gives 0.03 to 0.07 mg/kg IV according to recovery and blocker duration, with a maximum total of the lesser of 0.07 mg/kg or 5 mg. This label ceiling is not the recommended dose for every patient with minimal block. Inject over at least one minute. Give atropine or glycopyrrolate before or with neostigmine in a separate syringe; give the antimuscarinic first when bradycardia is present.
Quick check
Checking for saved practice…
Lesson
Use Antifibrinolytics With Route and Renal Discipline
Tranexamic acid and aminocaproic acid are lysine analogs that reduce fibrinolysis. Their value depends on a bleeding context in which fibrinolysis matters, while kidney clearance, thrombosis, seizure risk, and route errors define the safety boundary.
- Tranexamic acid
- Aminocaproic acid
- Plasminogen
- Renal function
- Route safety
Match the indication and timing; eligible trauma or postpartum treatment need not wait for proof of fibrinolysis.
Keep tranexamic acid physically and visually separated from neuraxial drugs.
Renal elimination makes dose and toxicity surveillance patient specific.
Block fibrinolysis deliberately
Both agents compete at lysine-binding sites involved in plasminogen and plasmin interaction with fibrin. This stabilizes formed clot but does not replace source control, fibrinogen, platelets, coagulation factors, temperature correction, or treatment of the actual bleeding mechanism.
Make tranexamic-acid route unmistakable
The FDA injection indication is short-term bleeding reduction in hemophilia during and after tooth extraction; trauma, other surgical, and obstetric regimens require their own evidence and protocols. Adjust for renal impairment. Clearly label the intravenous route and segregate from neuraxial medicines because accidental intrathecal or epidural administration has caused seizures, dysrhythmia, permanent injury, and death.
Identify the labeled tranexamic-acid regimen
For hemophilia tooth extraction, the injection label uses 10 mg/kg actual body weight before extraction with replacement therapy, then 10 mg/kg three to four times daily for 2 to 8 days. Its dose-reduction instructions apply before and after extraction. For example, serum creatinine 3.5 mg/dL falls in the 2.83 to 5.66 mg/dL band: 10 mg/kg once daily. Do not transfer this dental regimen automatically to another bleeding indication.
Match trauma treatment to the injury clock
For an adult bleeding or at risk of significant bleeding after trauma, the 2023 European guideline recommends TXA promptly and within 3 hours of injury: 1 g IV over 10 minutes, then 1 g over 8 hours. Do not delay eligible treatment for viscoelastic results. This is a guideline regimen outside the cited U.S. dental indication; continue definitive bleeding control and resuscitation.
Recognize postpartum bleeding early
WHO 2025 links first-response treatment to objectively measured blood loss: at least 300 mL with an abnormal hemodynamic sign, or at least 500 mL, whichever occurs first within 24 hours of birth. Abnormal signs include pulse over 100/min, systolic pressure below 100 mmHg, diastolic pressure below 60 mmHg, or shock index over 1. Shock index is pulse divided by systolic pressure. Watch especially closely in the first 2 hours. These criteria support prompt treatment and referral; they do not automatically mandate surgery. Evidence is strongest for facility vaginal births, so interpret cesarean measurements and anesthesia-related vital-sign changes clinically.
Separate postpartum treatment from routine prevention
WHO 2025 advises against routine TXA prophylaxis for all vaginal or cesarean births. It does not replace preventive uterotonics. This population-level recommendation preserves a role for clinical judgment when a high-risk patient is already bleeding before formal diagnostic thresholds are met. Treatment of established postpartum hemorrhage remains recommended. Store TXA separately from bupivacaine to reduce catastrophic neuraxial mix-ups.
Use the postpartum treatment schedule
WHO recommends early IV TXA alongside standard care for postpartum hemorrhage after vaginal or cesarean birth. Start within 3 hours of birth: 1 g over 10 minutes; repeat 1 g if bleeding persists after 30 minutes or recurs within 24 hours of finishing the first dose. The clock starts at birth, not diagnosis; WHO does not support starting treatment beyond that window. Do not wait to confirm the bleeding source before eligible treatment. Continue uterotonics, resuscitation and source control, and screen for contraindications such as a thromboembolic event during pregnancy. This treatment schedule is not an instruction for routine prophylaxis or an 8-hour trauma infusion.
Read concentration and infusion rate together
The current 100 mg/mL tranexamic-acid label lists 0.5 mL/min, never exceeding 1 mL/min, for undiluted administration. Its diluted rates are 5 mL/min at 10 mg/mL or 2.5 mL/min at 20 mg/mL. Each listed rate delivers 50 mg/min; the undiluted upper limit is 100 mg/min. Rapid administration can cause hypotension. Do not mix this product with blood or penicillin-containing solutions.
Screen beyond the route
Tranexamic-acid injection is contraindicated with active intravascular clotting, subarachnoid hemorrhage or hypersensitivity. Review prothrombotic medicines, including factor IX complex and anti-inhibitor coagulant concentrates and hormonal contraception. Seizures can occur even with IV use, especially at high surgical doses or increased exposure; renal adjustment and neurologic monitoring remain necessary.
Use aminocaproic acid only for fibrinolytic bleeding
Aminocaproic acid is primarily renally eliminated, and clearance approximates endogenous creatinine clearance. Distinguish primary fibrinolysis from disseminated intravascular coagulation before treatment. The label prohibits use with active intravascular clotting and states it must not be used in DIC without concomitant heparin; this is not a routine instruction to treat all DIC with both medicines. Avoid upper-tract hematuria use unless the expected benefit outweighs the risk of obstructing renal or ureteric clots.
Infuse aminocaproic acid deliberately
For acute bleeding from increased fibrinolysis, the label suggests 4 to 5 g in 250 mL diluent over the first hour, followed by 1 g/hour in 50 mL diluent, ordinarily for about 8 hours or until controlled. The 250 mg/mL stock requires dilution; do not give it as a rapid undiluted IV injection. Reassess dosing in severe renal failure. With prolonged treatment, monitor CK and muscle symptoms; stop for a CK rise suggesting myopathy.
Quick check
Checking for saved practice…
Module practice
Check the connections.
Each attempt draws 10 questions from the complete 81 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Core source material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- European trauma bleeding guideline, sixth edition (2023): Recommendation 23
- WHO: Tranexamic acid for postpartum hemorrhage (2017 dosing recommendation)
- WHO/FIGO/ICM: Consolidated postpartum hemorrhage guideline (2025)
- OAA/DAS: Obstetric difficult and failed intubation guideline (2015)
- SCCM 2016 Sustained Neuromuscular Blockade: Eye Care and Supportive Safeguards
- SCCM 2026 Neuromuscular Blockade in Adult ARDS
- Surviving Sepsis Campaign 2026 Adult Recommendations
- AAAAI: Soy and Egg Allergy and Propofol
- MHAUS: Dantrolene administration after an MH event
- DailyMed: RYANODEX prescribing information
- Saudi Critical Care Society and SSAI: Contextualized stress-ulcer prophylaxis guideline (2026)
- AHA. 2025 special circumstances of resuscitation: local anesthetic poisoning
- SCCM and ASHP: Prevention of Stress-Related Upper Gastrointestinal Bleeding in Critically Ill Adults
- ASRA: Checklist for Treatment of Local Anesthetic Systemic Toxicity
- MHAUS: Managing a Malignant Hyperthermia Crisis
- ASA: Practice Guidelines for Monitoring and Antagonism of Neuromuscular Blockade
- ISMP: 2026-2027 Targeted Medication Safety Best Practices for Hospitals
- DailyMed: Bupivacaine Hydrochloride Injection
- DailyMed: Succinylcholine Chloride Injection
- DailyMed: Rocuronium Bromide Injection
- DailyMed: Cisatracurium besylate prescribing information
- DailyMed: Vecuronium bromide prescribing information
- Caldwell et al. Vecuronium and 3-desacetylvecuronium in human volunteers (1994)
- DailyMed: BRIDION
- DailyMed: Neostigmine Methylsulfate Injection
- DailyMed: Propofol Injectable Emulsion
- DailyMed: Etomidate Injection
- DailyMed: Ketamine Hydrochloride Injection
- DailyMed: Tranexamic Acid Injection
- DailyMed: Aminocaproic Acid Injection